The mean time (± SD) taken for recovery of normal ambulation was 25±2 days in Group 1, 15±3 days in Group 2, 16±2 days in Group 3, and 11±4 days in Group 4. The lameness period in Group 4 was significantly shorter than those in Groups 1, 2, and 3 (p<0.05). The lameness period in Group 1 was significantly longer than those in Groups 2 and 3 (p<0.05). However, there were no differences in the mean lameness period between Groups 2 and 3 (Figure 6).

Subjects were excluded if they had any of the following: history of myocardial infarction, heart failure, or left ventricular (LV) ejection fraction <50%, greater than mild valvular stenosis or regurgitation or any regional wall motion abnormalities by cardiac imaging, chronic renal failure or serum creatinine ≥3.0 mg/dL, atrial fibrillation, diabetes mellitus requiring insulin therapy, systolic blood pressure ≥170 mm Hg or diastolic blood pressure ≥100 mm Hg at the most recent weight center visit, a history of current loop or thiazide diuretic use, a history of obstructive lung disease, or thyroid dysfunction. Female subjects who were pregnant or planned to become pregnant within 6 months were also excluded. The Partners Human Research Committee approved the protocol. All subjects provided informed consent.

These segments of the synthetic peptide AOD9604 have been researched for their in vivo effects in laboratory mice musculus. Results have shown that AOD9604 have resulted to a short-period increase in blood glucose and a more sustained increase in plasma insulin, together with other fragments such as 172-191, 177-191 and 178-191. In addition, the researchers have suggested that functionality of the peptide depends not only in the informational sequence but should also have the correct physical configuration (Ng and Borstein 1978). Also, AOD9604, being a region of high accessibility to proteases and also rich in proline, have been demonstrated to affect the conformational change in the cytoplasmic domain of the band 3 of erythrocyte membrane protein by serving as the hinge for the pivoting of the two subdomains. This then suggest that such residue is significant in conformational changes be serving as sites for peripheral protein binding in some body cells (Low et al. 1984).


CJC1295 is a 30 amino acid peptide, which primarily functions as a growth hormone releasing hormone analogue (mimicking the effect of GHRH). It was initially invented to treat deep fat deposits in people, because it is known that having an increase in our own growth hormone levels will target this. It stimulates production of our own growth hormone from the pituitary gland.

The peptide therapy protocols (Amino Acid Analogs) prescribed by TeleWellnessMD providers are also known as secretagogues (pronounced se-creta-gog), a substance that promotes secretion. These amino acid chains communicate with the body to produce or release growth hormone. Hence a secretagogue causes the body’s own natural processes to produce growth hormone. Secretagogues do not act as growth hormones but rather stimulate the pituitary gland to secrete your stored growth hormone. The subcutaneous injection route of growth hormone stimulation is a preferred route to help slow down age and environmental reductions in growth hormone levels.

The second long-term study (METAOD006) was a randomized, double-blind, placebo-controlled, multi-center, parallel group study conducted at 16 Australian hospitals and medical centres. In that study 534 were enrolled but of those 502 clinically obese subjects (BMI ≥ 30 kg/m2 and ≤ 45 kg/m2; Median BMI: 36.3 kg/m2, range: 30 to 45.2 kg/m2; 44% males and 56% females) were randomized to receive a daily dose of 0.25, 0.5 or 1mg AOD9604 or placebo for 24 weeks. Prior to this treatment period all subjects underwent a 4-week single-blind placebo run-in period. After cessation of the treatment a 4-week follow-up phase was performed.
The nature of the response to both hGH and AOD9604 is not clearly understood. We hypothesized that both molecules may influence the expression of the β3-adrenergic receptors (β3-ARs), the major lipolytic receptor in fat tissue. Both AOD9604 and hGH can increase β3-AR mRNA expression, as well as protein levels and function, in mouse and human cell lines in vitro (11). This response was investigated at the level of RNA and protein expression and function. The results for each mode of analysis were consistent in that both hGH and AOD9604 acted in a dose- and time-dependent manner to modulate the β3-AR response.
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Use only as directed. Consult your healthcare provider before using supplements or providing supplements to children under the age of 18. The information provided herein is intended for your general knowledge only and is not intended to be, nor is it, medical advice or a substitute for medical advice. If you have or suspect you have, a specific medical condition or disease, please consult your healthcare provider.
A total of 18 patients (3.6%) reported at least one SAE. The distribution of SAEs was similar among all treatment groups (Table 2). The most common SAEs reported were in the injury, poisoning and procedural complications body system class (6 patients, 1.2%). The others were general disorders and administration site conditions (2 patients; 0.4%), infections and infestations (2 patients; 0.4%), musculo-skeletal and connective tissue disorders (2 patients; 0.4%), and vascular disorders (2 patients; 0.4%).
Both AOD9604 and, to a greater extent, hGH increase body weight in lean mice, compared with saline-treated animals. This is in the absence of an increase in fat mass, which suggests an increase in lean body mass occurs with these compounds. This supports previous work with hGH in rodents and humans (17). Both compounds have also been previously shown to reduce body weight and adiposity in obese mice (11). The effects of hGH and AOD9604 occur without significant changes to caloric intake. It has been reported that hGH increases, reduces, or does not change food intake in which the differences are attributed to variations in hGH preparations, concentrations, and animals used between different laboratories.
Australian owned and operated., Peptide Clinics is fully licensed and registered with our offices located in Sydney, NSW, Australia. Specialising in the production of dr approved, clinical grade peptides, Peptide Clinics Australia guarantees optimal purity and potency of their peptide supplements. Our peptide treatments each come with a Certificate of Analysis, confirming the absence of contaminants. Our online gateway grants you a secure and confidential access to buy peptide supplements online in Australia coupled with expert medical guidance in their safe and efficient use. Our licensed Dr is a renowned expert in his field of anti-ageing, longevity and sports medicine. His supervision and specialisation in peptide supplementation significantly benefit each Peptide Clinic patient in Australia.
×